HOME >> MEDICINE >> NEWS
Baby and coated aspirin equally effective in thinning of blood when taken in combination with Plavix

Aspirin dose and type may not matter when taken in combination with Plavix for the purpose of thinning blood and possibly reducing the risk of stroke in people with cerebrovascular disease, according to research presented today at the American Stroke Association's 29th International Stroke Conference. The American Stroke Association is a division of the American Heart Association.

Northwestern Memorial researchers previously reported that the majority of patients who took baby or enteric-coated aspirin alone to prevent strokes were not getting the desired blood-thinning effects, causing concern among patients who chose to take coated or baby aspirin because of their reduced risk of gastrointestinal side effects.

"That's why we decided to study the efficacy of aspirin - in various doses and formulations - when taken in combination with Plavix," explains Mark J. Alberts, M.D., director of the stroke program at Northwestern Memorial Hospital and the study's lead author. "Plavix is a prescription antiplatelet medication that helps keep platelets in the blood from sticking together and forming clots. Plavix has fewer gastrointestinal side effects than adult-dose aspirin."

"While research has shown that the combined use of aspirin and Plavix provides an enhanced blood-thinning effect for patients trying to reduce their risk of vascular events, the optimal dose and formulation is unclear," according to Dr. Alberts. "This study is significant in that it continues to point researchers in the right direction - showing how we can maximize the effectiveness and safety of aspirin when used to reduce the risk of stroke."

Northwestern Memorial investigators collected data on aspirin dose, type (coated or uncoated), and demographic factors on a total of 69 in-patients and out-patients with cerebrovascular disease, including ischemic stroke and transient ischemic attacks (TIAs). Antiplatelet effects of aspirin were measured using a machine abo
'"/>

Contact: Patty Keiler
pkeiler@nmh.org
312-926-5900
Northwestern Memorial Hospital
5-Feb-2004


Page: 1 2

Related medicine news :

1. Loyola study shows drug-coated stent induces less inflammation than bare metal stent
2. Drug-coated stents effective in real world patients
3. The trojan clot-buster: Drug-coated red blood cells destroy blood clots from within
4. New study of coated stent long-term results disappointing
5. Silver-coated catheters cut infections & may save money, analysis finds
6. Many postmenopausal women with cardiovascular disease dont use lifesaving aspirin therapy
7. Survivors who stop taking aspirin increase risk of another stroke
8. Study says 43% of US adults at risk of heart disease are not utilizing aspirin therapy
9. Low-dose aspirin and stomach ulcer medications better for heart patients with GI complications
10. Statins and aspirin may protect against severe vision loss in elderly
11. One in five asthmatics are highly sensitive to aspirin

Post Your Comments:
(Date:4/14/2014)... been made in chemotherapy over the past decade, but ... continues to be a major challenge. , Nanotechnology ... the use of nanocarriers, or capsules, that can transport ... body. , The catch? These carriers are tiny, and ...
(Date:4/14/2014)... the 20th century, is currently losing a lot of ... at the University of South Carolina have just reported ... against so-called "superbugs." , Bacteria have been chipping away ... since their first wide-scale use as antibiotics in the ...
(Date:4/14/2014)... web information on colorectal cancer is too difficult for ... appropriate risks to and concerns of patients, a study ... a review of a dozen popular websites, most of ... were written beyond the recommended sixth-grade reading level, while ...
(Date:4/14/2014)... Inc., announced today a publication demonstrating that the company,s ... cells exposed to plasma samples of patients with a ... "TNT003, an inhibitor of the serine protease C1s, prevents ... was published on-line in the journal Blood ...
(Date:4/14/2014)... Child Development Institute have released their new study of ... success in kindergarten. According to FPG,s report, students enrolled ... of learning. , "Children are progressing at an ... than expected for normal developmental growth," said senior scientist ...
Breaking Medicine News(10 mins):Health News:Nano shake-up 2Health News:Penicillin redux: Rearming proven warriors for the 21st century 2Health News:Penicillin redux: Rearming proven warriors for the 21st century 3Health News:Website information on colon cancer too complex, fails to address key concerns 2Health News:Website information on colon cancer too complex, fails to address key concerns 3Health News:Ex vivo efficacy of C1s antibody as Complement inhibitor in cold agglutinin disease 2Health News:Study gives high marks to NC Pre-K program 2
(Date:1/15/2014)... , Jan. 15, 2014  Manufacturers, suppliers and distributors ... able to protect their most important business assets, ... ) Because of the highly-competitive ... remains one of the most litigious industry sectors ...
(Date:1/15/2014)... 2014 MultiCell Technologies, Inc. (OTC Bulletin Board: ... application concerning composition of matter, biological targets, mechanism of ... death.  This patent application describes a ... molecules (VSRNAs) which interfere with the basic homeostatic cellular ...
(Date:1/15/2014)... 2014  According to Millennium Research Group (MRG), the ... the United States and European ... expand moderately through 2022, with embolization particles representing ... interest in drug-eluting beads (DEBs) and radioembolization spheres ...
Breaking Medicine Technology:Intellectual Property Insurance for Medical-related Products and Services 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3
Cached News: